Lantern Pharma Inc. Lantern Pharma Inc.

Lantern Pharma Inc.

LTRN

Rank in Stocks #30257
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to... Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Share Price
$0.4331
Last synced: 2026-11-13
Market Cap
$5.38M
Change (1 day)
-5.97%
Change (1 year)
-86.51%
Country

Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this

Category

Healthcare
EPS for Lantern Pharma Inc. (LTRN)
EPS as of June 2026 TTM: $-1.62
According to Lantern Pharma Inc.'s latest financial reports, its current EPS (TTM) is $-1.62. At the end of 2025 the company had an EPS of $-1.57, an increase over its 2024 EPS of $-1.93K.
EPS history for Lantern Pharma Inc. from 2018 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-1.62 3.18%
2025 $-1.57 -99.92%
2024 $-1.93K 131,255.10%
2023 $-1.47 12.21%
2022 $-1.31 15.93%
2021 $-1.13 18.95%
2020 $-0.95 143.59%
2019 $-0.39 39.29%
2018 $-0.28 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 -45.06%
US
$15.66 -1,066.67%
US
$-7.07 336.42%
US
$-5.29 226.54%
AU
$12.73 -885.94%
BE

Questions about Lantern Pharma Inc.'s earnings per share (EPS)

What is Lantern Pharma Inc.'s earnings per share (EPS)?

Lantern Pharma Inc.'s earnings per share (EPS) over the last twelve months is $-1.62, as of Jun 2026.

What was Lantern Pharma Inc.'s earnings per share (EPS) in 2025?

In 2025, Lantern Pharma Inc.'s earnings per share (EPS) was $-1.57, compared with $-1.93K in 2024.

How has Lantern Pharma Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Lantern Pharma Inc.'s earnings per share (EPS) was highest in 2020 ($-0.95) and lowest in 2024 ($-1.93K).

How does Lantern Pharma Inc.'s earnings per share (EPS) compare with similar companies?

Lantern Pharma Inc.'s earnings per share (EPS) ($-1.62) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.